Invivo anti-Mouse CD86/B7-2 Recombinant mAb

CD86, also historically referred to as B7-2, is a type I transmembrane protein belonging to the immunoglobulin superfamily that serves as a critical costimulatory molecule primarily expressed on the surface of professional antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B cells. Functioning as a ligand for the CD28 and CTLA-4 (CD152) receptors on T cells, CD86 plays a pivotal role in regulating the adaptive immune response by providing the necessary "second signal" required for naive T cell activation, proliferation, and differentiation upon engagement with CD28, while its interaction with CTLA-4 delivers an inhibitory signal that helps maintain immune tolerance and prevent autoimmunity. Although it shares functional redundancy with its counterpart CD80 (B7-1), CD86 is typically constitutively expressed at low levels and is upregulated more rapidly than CD80 following APC activation, making it the dominant costimulatory molecule during the early phases of immune responses, which underscores its significance as a therapeutic target in various clinical contexts, including cancer immunotherapy, autoimmune diseases, and transplant rejection management.